Epidemiology of the myelodysplastic syndromes

Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition

Volumn , Issue , 2008, Pages 27-47

  Hamblin, Terry J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057482398     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 9th ed. Geneva: World Health Organization, 1977.
2. Reizenstein P, Dabrowski L. Increasing prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res 1991; 11:1069-1070.
3. International Statistical Classification of Diseases and Health Related Problems, (The) ICD-10 Second Edition. Geneva: World Health Organisation, 2005.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-199.
5. Linman EG, Bagby GC. The preleukemic syndrome (hemopoietic dysplasia). Cancer 1978; 42(Suppl 2):854-864.
6. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975 2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007 (accessed December 10, 2007.)
7. International Classification of Diseases for Oncology, 3rd ed. (ICD-O-3). Geneva: World Health Organisation, 2000.
8. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airline House, Virginia, November 1997. J Clin Oncol 2000; 18:2788-2789.
9. Fernandez-Ferrero S, Ramos F. Dyshaemopoietic bone marrow features in healthy subjects are related to age. Leuk Res 2001; 25:187-189.
10. Jacobs A. Leukaemia Research Fund annual guest lecture 1990. Genetics lesions in preleukaemia. Leukemia 1991; 5:277-282.
11. Busque L, Mio R, Mattioli J, et al. Non-random X-inactivation patterns in normal females: Lyonization ratios vary with age. Blood 1996; 88:59-65.
12. Cachia PG, Taylor C, Thompson PW, et al. Non-dysplastic myelodysplasia. Leukemia 1994; 8:677-681.
13. Cartwright RA, Alexander FE, McKinney PA, et al. Leukaemias and Lymphoma: An Atlas of distribution Within Areas of England and Wales 1984-1988. London: Leukaemia Research Fund, 1990.
14. Cartwright RA, McNally RJQ, Rowland DJ, et al. The Descriptive Epidemiology of Leukaemia and Related Conditions in Parts of the United Kingdom 1984-1993. London: Leukaemia Research Fund, 1997.
15. AulC, Gattermann N, SchneiderW. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82:358-367.
16. Radlund A, Thiede T, Hansen S, et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995; 54;153-156.
17. Mayanadie M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996; 74:288-290.
18. Bauduer F, Ducout L, Dastugue N, et al. Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 1998; 22:205-208.
19. Shimizu H, Matsushita Y, Aoki K, et al. Prevalence of myelodysplastic syndromes in Japan. Int J Hematol 1995; 61:17-22.
20. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87:743-745.
21. Phillips MJ, Cull GM, Ewings M. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 88:896-897.
22. Aul C, Germing U, Gattermann N, et al. Increasing incidence of myelodysplastic syndromes: Real or fictitious? Leuk Res 1998; 22:93-100.
23. Germing U, Strupp C, Kündgen A, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004; 89:905-910.
24. Beloosesky Y, Cohen AM, Grosman B, et al. Prevalence and survival in myelodysplastic syndrome of the refractory anemia type in hospitalized cognitively different geriatric patients. Gerontology 2000; 46:323-327.
25. Kuendgen A, Matsuda A, Germing U. Differences in epidemiology betweenWestern and Eastern countries: Ethnic differences or environmental influences. Leuk Res 2007; 31:103-104.
26. Mukiibi JM, Paul B. Myelodysplastic syndromes (MDS) in Central Africans. Trop Geogr Med 1994; 46:17-19.
27. Paydas S, Kocak R. Myelodysplastic syndrome in young age. Ann Intern Med 1994; 3:29-32.
28. Oguma S, Yoshida Y, Uchino H, et al. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: A co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health andWelfare. Leuk Res 1995; 19:219-225.
29. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998; 22:453-460.
30. Lee JH, Lee JH, Shin YR, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17:305-313.
31. Chatterjee T, Dixit A, Mohapatra M, et al. Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. Eur J Haematol 2004; 73:93-97.
32. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19:767-775.
33. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106:2633-2640.
34. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088.
35. Fenaux P, Preudhomme C, Estienne M, et al. De novo myelodysplastic syndromes in adult aged 50 or less. A report on 37 cases. Leuk Res 1990; 14:1053-1059.
36. Chang KL, O’Donnell MR, Slovak ML, et al. Primary myelodysplasia occurring in adults under 50 years old: A clinicopathologic study of 52 patients. Leukemia 2002; 16:623-631.
37. Breccia M, Mengarelli A, Mancini M, et al. Myelodysplastic syndromes in patients under 50 years old: A single institution experience. Leuk Res 2005; 29:749-754.
38. Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24:5358-5365.
39. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia 1998; Suppl. 1:S25-S29.
40. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17:277-282.
41. Emanuel PD. Myelodysplasia and myeloproliferative disorders in childhood: An update. Br J Haematol 1999; 105:852-863.
42. Zipursky A, Brown E, Christensen H, et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997; 21:97-101.
43. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group studies 2681 and 2891. Blood 1998; 91:608-615.
44. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9:1569-1572.
45. Hasle H, Wadsworth LD, Massing BG, et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106:1027-1032.
46. Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: A population-based study of incidence and survival. Br J Haematol 2003; 121:758-767.
47. Hasle H, Baumann I, Bergsträsser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18:2008-2014.
48. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: A study of 68 children and a new prognostic scoring system. Blood 1995; 85:1742-1750.
49. de Planque MM, Kluin-Nelemans HC, van Krieken HJ, et al. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br J Haematol 1988; 70:55-62.
50. Ishihara S, Nakakuma H, Kawaguchi T, et al. Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia. Int J Hematol 2000; 72:206-209.
51. Faber J, Lauener R, Wick F, et al. Shwachman-Diamond syndrome: Early bone marrow transplantation in a high risk patient and new clues to pathogenesis. Eur J Pediatr 1999; 158:995-1000.
52. Bertola DR, Sugayama SM, Albano LM, et al. Noonan syndrome: A clinical and genetic study of 31 patients. Rev Hosp Clin Fac Med Sao Paulo 1999; 54:147-150.
53. Stratton RF, Dobyns WB, Airhart SD, et al. New chromosomal syndrome: Miller-Dieker syndrome and monosomy 17p13. Hum Genet 1984; 67:193-200.
54. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92:267-272.
55. Alter BP. Inherited bone marrow failure syndromes. In: Handin RI, Lux SE, Stossel TP, ed. Blood: Principles and Practice of Hematology. Philadelphia: JB Lippincott Company, 1995:227-291.
56. Dokal I. Dyskeratosis Congenita in all its forms. Br J Haematol 2000; 110:768-779.
57. Kostmann R. Infantile genetic agranulocytosis: A new recessive lethal disease in man. Acta Paediatr Scand 1956; 45:1-12.
58. Grimwade DJ, Stephenson J, De Silva C, et al. Familial MDS with 5q-abnormality. Br J Haematol 1993; 84:536-538.
59. Kardos G, Veerman AJ, de Waal FC, et al. familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Med Pediatr Oncol 1996; 26:54-56.
60. Lune-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: A study of 167 patients. Blood 1999; 93:459-466.
61. Lucas GS, West RR, Jacobs A. Familial myelodysplasia. BMJ 1989; 299:551.
62. Olopade OI, Roulston D, Baker T, et al. Familial myeloid leukemia associated with the loss of the long arm of chromosome 5. Leukemia 1996; 10:669-674.
63. Wakita A, Komatsu H, Banno S, et al. Myelodysplastic syndrome developed in a mother and her son whose bone marrow karyotype showed monosomy 7. Rinsho Ketueki 1996; 37:311-316.
64. Kardos G, Veerman AJ, de Waal FC, et al. Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Med Pediatr Oncol 1996; 26:54-56.
65. Gao Q, Horwitz M, Roulsdon D, et al. Susceptibility gene for familial acute myeloid leukaemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer 2000; 28:264-272.
66. Kumar T, Mandla SG, Greer WL. Familial myelodysplastic syndrome with early age of onset. Am J Hematol 2000; 64:53-58.
67. Mandala SG, Goobie S, Kumar RT, et al. Genetic analysis of familial myelodysplastic syndrome: absence of linkage to chromosomes 5q31 and 7q22. Cancer Genet Cytogenet 1998; 106:113-118.
68. Hiraga H, Yabe H, Nagai K, et al. Myelodysplastic syndrome in a patient with familial Pelger-Huet anomaly. Rinsho Ketuski 1991; 32:1453-1457.
69. Shpilberg O, Dorman JS, Shahar A, et al. Molecular epidemiology of hematological neoplasms present status and future directions. Leuk Res 1997; 21:265-284.
70. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: New approaches to human cancer causation. J Chronic Dis 1982; 35:581-600.
71. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 2007; 447:725-729.
72. Nijnik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007; 447:686-690.
73. Jankowska AM, Gondek LP, Szpurka H, et al. Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia 2007 Dec 6 (Epub ahead of print).
74. Bhatla D, Gerbing RB, Alonzo TA, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: A report from the children’s oncology group. Leukemia 2007 Nov 22 (Epub ahead of print).
75. Xi T, Jones IM, MohrenweiserHW. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 2004; 83:970-979.
76. Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 2007; 21:1413-1422.
77. Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: Susceptibility and incidence. Haematologica 2007; 92:1389-1398.
78. Rund D, Krichevsky S, Bar-Cohen S, et al. Therapy-related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19:1919-1928.
79. Fern L, Pallis M, Carter G, et al. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004; 126:63-71.
80. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapyrelated leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6:4091-4095.
81. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 2001; 98:11592-11597.
82. Chen H, Sandler DP, Taylor JA, et al. Increased risk for myelodysplastic syndrome in individuals with glutathione transferase theta (GSTT1) gene defect. Lancet 1996; 347:295-297.
83. Sasai Y, Horiike S, Misawa S, et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res 1999; 23:975-981.
84. Davies SM, Robison LL, Buckley JD, et al. Glutathione S-transferase polymorphisms in children with myeloid leukemia: A Children’s Cancer Group Study. Cancer Epidemiol Biomarkers Prev 2000; 9:563-566.
85. Arruda VR, Lima CS, Grignoli CR, et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol 2001; 66:383-388.
86. Haase D, Binder C, Bünger J, et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002; 26:249-254.
87. Sutton JF, Stacey M, Kearns WG, et al. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 2004; 42:122-126.
88. Moreland HS. The occurrence of malignancy in radioactive persons. Am J Cancer 1931; 15:2435-2516.
89. Hamilton-Paterson JL. Pre-leukaemic anaemia. Acta Haematol 1949; 2:307-316.
90. Evans RD. The effects of skeletally deposited alpha-ray emitters in man. Br J Radiol 1966; 39:881-895.
91. Finch SC, Hoshino T, Lamphere JP, et al. Peripheral blood changes preceding the development of leukemia in atom bomb survivors in Hiroshima and Nagasaki. In: Seno S, Takaku F, Irino S, eds. Topics in Haematology, 16th International Congress of Haematology. Amsterdam: Exerpta Medica, 1977:97-98.
92. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998; 95:13176-13181.
93. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25:292-300.
94. Tucker A, Guler N. Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: A case report. Hematol Cell Ther 1999; 41:195-196.
95. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104:822-828.
96. Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91:1546-1550.
97. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: A survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109:2794-2796.
98. Browning E. Toxicity and Metabolism of Industrial Solvents. Amsterdam: Elsevier, 1965:3-65.
99. Aksoy M, Erdem S, Dincol G. Types of leukemia in chronic benzene poisoning. Acta Haematol 1976; 55:65-72.
100. Aksoy M. Malignancies due to occupational exposure to benzene. Am J Indust Med 1985; 7:395-402.
101. Farrow A, Jacobs A, West RR. Myelodysplasia, chemical exposure and other environmental factors. Leukemia 1989; 3:33-35.
102. West RR, Stafford DA, Farrow A, et al. Occupational and environmental exposures and myelodysplasia: A case control exposure. Leuk Res 1995; 19:127-139.
103. Goldberg H, Lusk E, Moore J, et al. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: Correlation with chromosomal patterns and data on patients without hematological disease. Cancer Res 1990; 50:6876-6881.
104. Rigolin GM, Cuneo A, Roberti MG, et al. Exposure to myelotoxic agents and myelodysplasia: Case-control study and correlation with clinicobiological findings. Br J Haematol 1998; 103:189-197.
105. Ido M, Nagata C, Kawakami N, et al. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 1996; 20:727-731.
106. Nagata C, Shimizu H, Hirashima K, et al. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res 1999; 23:57-62.
107. Nisse C, Haguenoer JM, Grandbastien B, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol 2001; 112:927-935.
108. Tsai SP, Fox EE, Ransdell JD, et al. A hematology surveillance study of petrochemical workers exposed to benzene. Regul Toxicol Pharmacol 2004; 40:67-73.